Skip to main content
. Author manuscript; available in PMC: 2019 Mar 26.
Published in final edited form as: Ocul Surf. 2018 Jul 7;16(4):463–469. doi: 10.1016/j.jtos.2018.07.004

Fig. 1.

Fig. 1.

Effect of rosiglitazone on Ki-67 labeling in cultured hMGEC. (A) Control cells, which were grown in DMEM/F12 with EGF for 4d showed about 15% positive labeling (green) and (B) cells treated with rosiglitazone showed almost complete loss of Ki67 labeling. (C) Cells treated with a PPARγ antagonist T0070907 showed about 11% positive labeling and (D) cells treated with T0070907 and rosiglitazone showed similar labelling. (E) Bar graph showing labeling index for cells treated with different concentrations (10, 30, and 50 μM) of rosiglitazone, T0070907, and T0070907 plus rosiglitazone (30 μM) for 2d to 4d. There was a significant decrease in Ki-67 labeling at 2d to 4d after treatment with rosiglitazone in a time and concentration dependent manner. Cells treated with T0070907 showed significantly greater positive labeling than cells treated with rosiglitazone (P < 0.05).